Description

Tamoxifen 10 mg Tablets — Swiss Remedies

Brand: Swiss Remedies
Category: SERM Research Compound
Content: 100 tablets × 10 mg (1,000 mg total)
Price: €29
Manufactured in: Switzerland

🧪 Product Overview

Tamoxifen 10 mg is a selective estrogen-receptor modulator (SERM) widely used in
endocrinology, oncology, and reproductive-physiology research. By antagonizing ER-α/β
receptors, tamoxifen reduces estrogenic negative feedback on the hypothalamic–pituitary–gonadal (HPG) axis,
thereby increasing luteinising hormone (LH), follicle-stimulating hormone (FSH), and endogenous testosterone
levels in male research models.

In female models, tamoxifen remains the reference anti-estrogen for ER-positive tumor studies
and is foundational in breast-cancer research methodologies. Its long half-life (parent: 4–11 days;
active metabolite endoxifen: 50–70 h) ensures stable receptor occupancy and consistent endocrine modulation.

✅ Key Research Highlights

HPG-axis stimulation:
Studies show that 10–20 mg/day for 3 months can double serum testosterone in hypogonadal men (PMC).

Gynecomastia regression models:
Clinical literature demonstrates breast-tissue reduction with 10–20 mg/day during anabolic-steroid cycles.

Anti-estrogen gold standard:
Primary SERM model for ER-positive tumor studies and comparative endocrine research.

Pharmacokinetics:
~100% oral bioavailability; parent half-life 4–11 days; active metabolite half-life 50–70 h.

Research logistics:
Film-coated tablets stable ≤25 °C with 36-month shelf-life, simplifying storage compared to parenteral SERMs.

🧬 Suggested Laboratory Applications

• ER-α/β modulation studies
• HPG-axis regulation and testosterone-restoration experiments
• Gynecomastia and anti-estrogenic pathway research
• ER-positive tumor and endocrine oncology models
• Comparative SERM pharmacology and metabolite profiling

📊 Technical Specifications

❄️ PubChem-Supported Research Insights

• Strong ER-blockade increases gonadotropin secretion
• Primary comparator in SERM and anti-estrogen studies
• Supports ER-positive cancer research and endocrine therapy modeling
• Long half-life enables extended receptor modulation
• Active metabolites contribute to prolonged efficacy and pharmacodynamics

⚠️ Documented Research Side Effects

• Hot-flushes and vasomotor symptoms
• Visual blurring and reported cataract risk
• Thrombo-embolic events and lipid-profile shifts
• Reduced bone-mineral density during prolonged exposure
• Fatigue and mood changes reported in some literature

🧯 Handling & Compliance

For Research Use Only – not for dietary, therapeutic, or veterinary use.
Tamoxifen is prohibited under WADA S4 (Hormone Modulators); any exposure may trigger positive doping results.
Purchase confirms qualified-researcher status and acceptance of all handling liability.
Store sealed, protected from heat and light, and follow institutional chemical-safety protocols.